Translating genomic information into clinical medicine: Lung cancer as a paradigm

Genome Research

Volumn 22, Issue 11, 2012, Pages 2101-2108

  Levy, Mia A ^a,b   Lovly, Christine M ^a,b   Pao, William ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; IMATINIB; PACLITAXEL; VEMURAFENIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; CLINICAL MEDICINE; DISEASE COURSE; DNA SEQUENCE; GENE MUTATION; GENE SEQUENCE; GENOME; HUMAN; INTRACELLULAR SIGNALING; LABORATORY; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; UNITED STATES;

ANTINEOPLASTIC AGENTS; GENES, NEOPLASM; GENETIC TESTING; GENOMICS; HUMANS; LUNG NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84868331240     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.131128.111     Document Type: Review

References (71)

1. Andrews J, Yeh P, Pao W, Horn L. 2011. Molecular predictors of response to chemotherapy in non-small cell lung cancer. Cancer J 17:104-113.
2. Bergethon K, Shaw AT, Ignatius Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, et al. 2012. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30:863-870.
3. E17K in human solid tumours. Oncogene 27:5648-5650.
4. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, et al. 2002. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997-7000.
5. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, et al. 2007. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356:11-20.
6. De Greve J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, Veld PI, Schallier D. 2012. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 76:123-127.
7. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, et al. 2010. Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med 2:146-158.
8. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, et al. 2008. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069-1075.
9. Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A. 2008. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes 1:14. doi:10.1186/1756-0500-1-14.
10. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al. 2001. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037.
11. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, et al. 2011. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PloS One 6: e20351. doi:10.1371/journal.pone.0020351.
12. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043.
13. Febbo PG, Ladanyi M, Aldape KD, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S et al. 2011. NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J Natl Compr Canc Netw 9: S1-S32.
14. Gautschi O, Pauli C, Strobel K, Hirschmann A, Printzen G, Aebi S, Diebold J. 2012. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol doi:10.1097/JTO.0b0.13e318262903.
15. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, et al. 2004. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597.
16. Holman CM. 2012. Debunking the myth that whole-genome sequencing infringes thousands of gene patents. Nat Biotechnol 30:240-244.
17. Horn L, Chen H, Lovly CM, Andrews J, Yeh P, Levy MA, Pao W. 2011. DIRECT: DNA-mutation Inventory to Refine and Enhance Cancer Treatment\-A catalogue ofclinically relevant somatic mutations in lung cancer. In J Clin Oncol 29, Supplement, abstract no. 7575. 2011 ASCO Annual Meeting, Chicago, Illinois.
18. International Union Against Cancer (UICC). 1968. TNM classification of malignant tumours. Geneva, Switzerland.
19. Jensen K, Murray F. 2005. Intellectual property landscape of the human genome. Science 310:239-240.
20. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, Kim YT, Kim JI, Kang JH, Seo JS. 2012. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22:436-445.
21. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, Kobayashi Y, Yano M, Fujii Y. 2006. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54:209-215.
22. Kean S. 2011. Human genome 10th anniversary. The Human Genome (patent) Project. Science 331:530-531.
23. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792.
24. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, et al. 2012. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18:375-377.
25. Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R, et al. 2008. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275-4283.
26. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, et al. 2010. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703.
27. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, et al. 2001. Initial sequencing and analysis of the human genome. Nature 409:860-921.
28. Lee W, Jiang Z, Liu J, Haverty PM, Guan Y, Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, et al. 2010. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 465:473-477.
29. Li C, Fang R, Sun Y, Han X, Li F, Gao B, Iafrate AJ, Liu XY, Pao W, Chen H, et al. 2011. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE 6: e28204. doi:10.1371/journal.pone. 0028204.
30. Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, Curran JA, Balasubramanian S, Bloom T, Brennan KW, et al. 2012. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18:382-384.
31. Lovly CM, Pao W. 2012. Escaping ALK inhibition: Mechanisms of and strategiesto overcome resistance. Sci Transl Med 4:120ps2. doi:10.1126/ scitranslmed.3003728.
32. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
33. Macconaill LE, Garraway LA. 2010. Clinical implications of the cancer genome. J Clin Oncol 28:5219-5228.
34. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al. 2010. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380-2388.
35. Malanga D, Scrima M, DeMarco C, Fabiani F, De Rosa N, De Gisi S, Malara N, Savino R, Rocco G, Chiappetta G, et al. 2008. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7:665-669.
36. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, Ding L, Mardis ER, Wilson RK, Solit D, et al. 2008. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 68:5524-5528.
37. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et al. 2009. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 11:121-128.
38. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. 2009. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957.
39. Neubauer MA, Hoverman JR, Kolodziej M, Reisman L, Gruschkus SK, Hoang S, Alva AA, McArthur M, Forsyth M, Rothermel T, et al. 2010. Cost effectiveness of evidence-based treatment guidelines for the treatment of non-small-cell lung cancer in the community setting. J Oncol Pract 6:12-18.
40. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
41. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ. 2011. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29:2046-2051.
42. Pao W, Chmielecki J. 2010. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10:760-774.
43. Pao W, Hutchinson KE. 2012. Chipping away at the lung cancer genome. Nat Med 18:349-351.
44. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci 101:13306-13311.
45. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. 2005a. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73. doi:10.1371/journal.pmed.0020073.
46. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. 2005b. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2: e17. doi:10.1371/journal.pmed.0020017.
47. Pao W, Kris MG, Iafrate AJ, Ladanyi M, Janne PA, Wistuba II, Miake-Lye R, Herbst RS, Carbone DP, Johnson BE, et al. 2009. Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res 15:5317-5322.
48. Pao W, Iafrate AJ, Su Z. 2011. Genetically informed lung cancer medicine. J Pathol 223:230-240.
49. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, et al. 2008. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68:9375-9383.
50. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et al. 2009. Phase III trialof cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27:1227-1234.
51. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, Nafa K, Riedel ER, Hsu M, Pao W, et al. 2008. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14:5731-5734.
52. Riely GJ, Marks J, Pao W. 2009. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc 6:201-205.
53. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, et al. 2011. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3: doi:10.1126/scitranslmed.3003261.
54. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. 2006. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550.
55. Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J, Zhu J, Johnson D, Group TECO. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98.
56. Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, et al. 2011. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22:2616-2624.
57. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U, et al. 2009. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27:4247-4253.
58. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S, Jurisica I, Giordano TJ, Misek DE, et al. 2008. Gene expression-based survival prediction in lung adenocarcinoma: a multisite, blinded validation study. Nat Med 14:822-827.
59. Siegel R, Ward E, Brawley O, Jemal A. 2011. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236.
60. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, et al. 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561-566.
61. Sonobe M, Manabe T, Wada H, Tanaka F. 2006. Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. J Mol Diagn 8:351-356.
62. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, et al. 2011. Aplatform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn 13:74-84.
63. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, Han X, Tian W, Pao W, Chen H, et al. 2010. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol 28:4616-4620.
64. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, et al. 2012. RET, ROS1 and ALK fusions in lung cancer. Nature Med 18:378-381.
65. Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba I. 2006. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 1:231-239.
66. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, Smith HO, Yandell M, Evans CA, Holt RA, et al. 2001. The sequence of the human genome. Science 291:1304-1351.
67. Weinstein I. 2002. Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297:63-64.
68. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, et al. 2007. Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893-898.
69. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, Ullrich RT, Menon R, Maier S, Soltermann A, et al. 2010. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93. doi:10.1126/scitranslmed. 3001451.
70. Wheat PF. 2001. History and development of antimicrobial susceptibility testing methodology. J Antimicrob Chemother 48 (Suppl 1):1-4.
71. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, Cheng CL, Yu CJ, Lee YC, Chen HS, et al. 2008. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 13:48-57.